Verisense Health

What Verisense Health does

Verisense Health, Inc. is a digital health software and data management company that provides wearable-sensor-based data collection services to pharmaceutical and biotech sponsors running clinical trials. The company was founded in January 2023 as a spin-off from Dublin-based Shimmer Research, inheriting its Verisense wearable platform and Digital Health Panel, and is headquartered in Cambridge, Massachusetts, with engineering operations in Malaysia and a manufacturing relationship back to Shimmer in Dublin.

The company's core technology stack combines research-grade hardware (the Verisense Smart Watch with raw 3-axis accelerometer, PPG, ECG, and temperature sensors; the Verisense IMU sensor; and the Verisense Pulse+ PPG/GSR module), the open-source GGIR algorithm for raw accelerometer processing, the IRB-approved Digital Health Panel for longitudinal participant recruitment, and the Verisense Digital Biobank—a repository of raw sensor data from 500+ studies and 1M+ people, integrated with Datavant's tokenization layer for linkage to real-world data including claims, EMR, labs, genomics, imaging, and mortality records. Sponsors engage through Companion Studies (inviting existing trial participants to the DHP), Turnkey Studies (DHP recruits to spec), or Registry Studies, and pay only for the data received rather than for hardware or software licenses.

Verisense Health generates revenue primarily through per-participant data collection fees (Smart Watch studies start at under $100 per participant), direct sales of hardware at sub-$100 pricing, and emerging monetization of Digital Biobank data access. It sells directly to enterprise pharma and biotech sponsors via a field-sales motion supplemented by conference presence at SCOPE, DPHARM, Mobile in Clinical Trials, CNS Summit, and DIA. The company's initial therapeutic focus is brain health indications including Alzheimer's disease, bipolar disorder, and Parkinson disease. Regulatory credentials include CE Class I medical device certification for the IMU sensor, FDA 510(k) exemption, and ISO 13485:2016-compliant manufacturing through its Shimmer parent.

Name

Verisense Health

Legal name

Verisense Health, Inc.

Website

https://verisense.net

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Verisense Health is a digital health data management company that provides wearable sensor platforms and the Digital Health Panel for cost-efficient clinical trial data collection by pharmaceutical and biotech sponsors.

Ownership category

akta.pro rank

Product category

Clinical Trial Wearable Technology

NAICS

Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH), Post-Acute Care & Rehabilitation Monitoring (Home Health, PT/OT) (HLACAPAE)

Keywords

• Digital health data collection
• Wearable sensors clinical trials
• Digital biobank platform
• Remote patient monitoring
• Digital biomarker development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Digital Health Data Collection Services: Sponsors pay for data generated from clinical trials using the Verisense platform. Pricing is per participant (studies starting at under $100 per participant for Smart Watch). Sponsors pay only for data they receive, not for hardware, software, or services separately. Revenue derived from companion studies, turnkey studies, and registry studies conducted via the Digital Health Panel.
2. Hardware Sales — Verisense Smart Watch: Sale of the Verisense Smart Watch hardware at under $100 per unit. The Smart Watch is a participant-friendly research-grade wearable device providing raw sensor data at a fraction of comparable solutions' cost.
3. Digital Biobank Data Access: The Digital Biobank provides researchers access to cataloged raw digital sensor data, harmonized datasets, and algorithm application capabilities. Researchers can locate relevant data from catalogued datasets, harmonize different datasets, and apply algorithms. Revenue model for biobank access is not explicitly detailed but represents a data monetization stream.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Verisense Health provides a digital health data collection platform for clinical trials, combining the Verisense Smart Watch research-grade wearable (under $100 per participant) with the Digital Health Panel (IRB-approved longitudinal study infrastructure) and the Digital Biobank (repository of raw sensor data with patient-reported outcomes and Datavant-tokenized real-world data). Sponsors contract directly with Verisense for Companion Studies, Turnkey Studies, and Registry Studies, paying only for the data they receive.

Product overview

Verisense Health offers a unified digital health data collection platform for clinical trials consisting of hardware, software, and data services. The core product portfolio includes the Verisense Smart Watch (research-grade wrist-worn device under $100), the Verisense IMU Sensor (inertial measurement unit), and Verisense Pulse+ (PPG/GSR module). These devices collect continuous raw sensor data that is processed using the open-source GGIR algorithm and managed through the Verisense Web Portal. The Digital Health Panel (DHP) provides an IRB-approved infrastructure for participant recruitment and data collection, supporting Companion Studies, Turnkey Studies, and Registry Studies. All data is aggregated in the Digital Biobank, a repository containing data from 500+ studies with over 1 million people. The platform integrates with Datavant's data connectivity platform to link sensor data with real-world data sources. Verisense Health was founded in January 2023 as a spin-off from Shimmer Research and is headquartered in Cambridge, MA with offices in Malaysia.

Differentiator

Problem solved

Functional benefit

Brands

• Verisense Digital Biobank: A repository of raw digital sensor data with associated patient reported outcomes and tokens to enable access to Real World Data (RWD), including medical records, claims data, and pharmacy data on an anonymous basis.
• Digital Health Panel (DHP)
• Verisense Smart Watch

Products and services

• Verisense Smart Watch A participant-friendly research-grade smart watch for clinical trials providing raw 3-axis accelerometer, PPG (red and green), ECG, and body temperature data, with approximately 2-week battery life, automatic cloud data upload, and compatibility with participants' own smartphones via iOS/Android apps. Priced at under $100 per participant.
• Verisense Digital Biobank A repository of raw digital sensor data with associated patient-reported outcomes and tokens enabling HIPAA-compliant access to real-world data including medical records, claims data, and pharmacy data. Contains data from 500+ studies covering more than 1 million people, with an AI-powered Dataset Cataloger for metadata extraction and harmonization.
• Digital Health Panel (DHP) An IRB-approved longitudinal study recruiting clinical trial participants and healthy volunteers who contribute medical history, wearable sensor data, and monthly survey data; data can be tokenized and linked to claims, EMR, and pharmacy data via Datavant. Serves as the infrastructure for Companion, Turnkey, and Registry Studies.
• Companion Study A study offering where sponsors invite their existing clinical trial participants to join the DHP; sponsors pay only for the data received while Verisense monitors compliance and quality-checks data before transfer to the sponsor.
• Turnkey Study A study offering where the DHP recruits participants according to sponsor specifications, with protocol adjustments available to meet sponsor requirements and full DHP infrastructure management by Verisense; leverages a partner's 400,000-person health panel.
• Registry Studies A study offering available through Verisense Health's DHP platform infrastructure for sponsors who need to recruit participants from existing patient registries.
• Verisense IMU Sensor An Inertial Measurement Unit sensor providing raw 3-axis accelerometer and 3-axis gyroscope data at configurable sample rates (12.5Hz–200Hz accelerometer, 12.5Hz–3332Hz gyroscope), with up to 6 months battery life and IP67 waterproof rating. CE certified Class I medical device and FDA listed Class II 510(k) exempt.

Quantifiable outcome

• More than 90% wear compliance in clinical studies
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature8 records

Partnerships

Three partnerships are on record, tiered core and minor.

• DatavantcoreTechnology or Integration · 6 February 2024Verisense Health has adopted Datavant's data connectivity platform and tokenization technology to link its Digital Health Panel to other real-world data (RWD) sources. Datavant's ecosystem includes 500+ data partners with linkable claims, electronic medical records, laboratory results, social determinants, genomics, imaging, mortality, and registry data. This enables HIPAA-compliant matching of patient records across datasets while preserving patient privacy, significantly expanding the richness of the Digital Biobank.
• ClearSky Medical DiagnosticscoreStrategic or Co-development Partner · 19 June 2019Shimmer Research and ClearSky Medical Diagnostics partnered to bring advanced analytic capabilities to wearable sensor data for central nervous system (CNS) diseases. The partnership combines Shimmer's Verisense wearable sensors platform with ClearSky's algorithms and machine learning to transform wearables data into actionable insights for CNS disease research.
• 400,000 Person Health Panel ProviderminorStrategic or Co-development PartnerVerisense Health leverages a partner's 400,000-person health panel for Turnkey Studies, where the DHP recruits participants according to sponsor specifications. This partnership enables recruitment at scale for sponsors who need specific demographic or condition-based participant groups.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Cala Health: Cala Health develops wearable neurostimulation devices and collects sensor data for movement disorders. While therapeutic rather than purely observational, it competes for the same pharma CNS research budgets that Verisense targets.
• Biofourmis: Biofourmis offers a remote patient monitoring + AI analytics platform used in decentralized clinical trials and post-market studies. It overlaps with Verisense's DHP/Companion Study offering for pharma sponsors and has raised significantly more capital.
• Evidation Health: Evidation operates a large direct-to-consumer health data platform and conducts decentralized real-world evidence studies. It overlaps with Verisense's longitudinal data collection and biobank thesis, particularly for healthy-volunteer and consumer-grade cohorts.
• SnapIoT / Snap40 (now Huma): Huma (formerly Snap40) provides a remote patient monitoring platform for decentralized clinical trials and care delivery, with a wearable-plus-cloud model that overlaps with Verisense's DHP and Companion Study offerings.

Broad incumbents

• iRhythm Technologies: iRhythm's Zio wearable cardiac monitor combines a small wearable patch with cloud-based analytics — a comparable medical-grade wearable + AI data platform business model, focused on cardiology rather than CNS/activity.
• Medidata (Dassault Systèmes): Medidata is the leading clinical trial technology platform (Rave, Patient Cloud, Sensor Cloud) and competes with Verisense in digital biomarker capture, though as part of a much broader EDC/CTMS portfolio rather than a wearable specialist.
• Clario: Clario (formerly ERT/Bioclinica) provides endpoint data capture solutions for clinical trials including wearable/sensor integrations. It is a broad incumbent that competes with Verisense for pharma digital endpoint business, particularly in respiratory, cardiac and CNS.

Direct peers

• Empatica: Empatica makes medical-grade wearable sensors (EpiMonitor, Embrace) for clinical research and digital biomarker development, including CNS indications like epilepsy. It targets the same pharma/biotech sponsor customers with a comparable raw-sensor-plus-cloud proposition.
• VivoSense: VivoSense provides wearable sensor analytics and regulatory-grade endpoints for clinical trials, with a similar focus on raw data, validated algorithms, and pharma/CNS customers. It is one of the closest direct competitors in the digital endpoint development space.
• ActiGraph: ActiGraph is the dominant research-grade accelerometer used in clinical trials and academic research. It competes head-to-head with Verisense's IMU sensor and Smart Watch in activity/sleep endpoints for pharma-sponsored studies, with a much larger installed base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/VerisenseDigitalHealth
• LinkedInlinkedin.com/company/verisense-health
• Xx.com/NetVerisense

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verisense Health